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Introduction
2
Pseudomonas aeruginosa is a major cause of healthcare-associated infections. 
9
surveillance of isolates from the community is less frequent than from healthcare settings and 10 nationwide resistance rates in community setting are less well understood.
12
The Veterans Affairs (VA) is the largest integrated healthcare system in the United States (US), 
19
Methods
20
We evaluated antimicrobial susceptibility from all VA hospitals, long-term care units and outpatient 
21
24
divided by the total number of isolates tested. We presented overall rates of antibiotic resistance 1 region. All analyses will be performed with SAS (SAS, Cary, NC, Version 9.2).
3
Results
4
We identified 24,562 P. aeruginosa isolates from 126 VA facilities over the 5-year study period;
5
82% were from inpatient settings. Most isolates were obtained from white (72%), male (97%),
6
Veterans 65 years and older (59%). Resistance was highest for fluoroquinolones (33%) and 7 lowest for the piperacillin class (piperacillin/tazobactam and piperacillin, 21%; Table 1 ).
8
Resistance to carbapenems, extended-spectrum cephalosporins, and aminoglycosides was 24-9 25%. Resistance was higher in inpatient settings (Table 1 ) and in respiratory isolates (Table 2) .
10
Prevalence of MDR was 20% overall (22% and 11% for inpatient and outpatient settings,
11
respectively; and 21% and 17% for respiratory and bloodstream isolates, respectively). 
6
among labs may have impacted our findings. We applied CLSI susceptibility breakpoints where 7 MIC data was available, however MIC data was not available for all isolates. In such cases we 8 had to rely on the interpretation as provided by the testing microbiology laboratory. Finally, the 9 generalizability of the study population and results are limited to the VA, a fully integrated 10 healthcare system consisting of largely older, white male patients.
12
In summary, among nearly 25,000 clinical P. aeruginosa respiratory and bloodstream isolates, 
6
Extended-spectrum cephalosporins category included ceftazidime and cefepime.
7
Fluoroquinolones category included levofloxacin and ciprofloxacin.
8
Aminoglycosides category included amikacin, gentamicin, and tobramycin.
9
Carbapenems category included imipenem, meropenem, and doripenem.
10
Piperacillins included piperacillin and piperacillin/tazobactam.
11
CDC MDR was defined as non-susceptibility to at least one agent in at least three of the 12 following 5 categories: aminoclycosides, carbapenems, extended-spectrum cephalosporins,
13
fluoroquinolones, and piperacillins. 
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fluoroquinolones, and piperacillins.
